- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05033301
Evaluating the Effectiveness of the Nurse Ned Clinic (NurseNed)
Virtualizing Survivorship: Implementing a More Timely and Comprehensive Model of Follow-up Care: Effectiveness Evaluation Phase
Study Overview
Detailed Description
Prostate cancer (PCa) is the most common cancer among Canadian men, with over 25,000 diagnosed yearly. While advances in treatment and care, including the PSA (prostate-specific antigen) test have resulted in more men entering survivorship and living longer, many continue to experience undesirable symptoms, side effects and psychosocial concerns. The current healthcare system is not optimized to deliver survivorship care at scale and struggles to support the increasing number of survivors across the cancer care continuum. Increasing patient loads in specialty clinics result in brief and infrequent follow-up visits, leaving patients without the opportunity to ask questions and fully understand their health status, all the while tasking providers with making quick and effective treatment decisions with minimal patient information or interaction.
In order to address this increasing need for improved care delivery, investigators have developed the Ned ("No Evidence of Disease") PCa survivorship platform, which allows patients to access clinical information (i.e. lab results), virtually complete patient reported outcomes (PROs) on their quality of life, and complete virtual visits with their specialist. Despite the promise and potential of Ned, ongoing evaluation of this platform shows specialists often lacked the availability and flexibility to consistently review ePROs and lab results prior to a study visit. In response, researchers aim to expand the current Ned platform to design, develop and implement a digitally mediated nurse-led survivorship care model that can address the growing needs of prostate cancer survivors and healthcare providers at scale.
In this trial, investigators aim to evaluate the effectiveness of a nurse-led survivorship care model by comparing the clinical outcomes of patients enrolled in the Specialist Ned Clinic (control) for their PCa follow-up care and those that will be enrolled into the Nurse Ned Clinic (intervention) a year later. Participants will be enrolled in the study for one year, and will be asked to complete standardized questionnaires related to their PCa follow-up care at the start of the study, 6-months into using their respective Ned Clinic and at study completion.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Denise Ng, MSc
- Phone Number: 437-777-9562
- Email: denise.ng@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Recruiting
- University Health Network (Princess Margaret Hospital)
-
Contact:
- Denise Ng
- Email: denise.ng@uhn.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older
- Completed curative-intent treatment
- Receiving PCa survivorship care at University Health Network (UHN), Trillium Health Partners (THP), Niagara Health System (NHS), Prostate Cancer Centre - Calgary (PCCC), or Queen Elizabeth II Health Sciences Centre (QEII HSC)-affiliated hospital
- Low risk of recurrence as determined by their treatment specialist
- Adequate English ability (or a caregiver willing to provide translation) to complete study activities as determined by research assistant
- Have an email address (or be able to use the email address of a caregiver)
Exclusion Criteria:
Patients with metastatic PCa are not eligible to participate in this research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Specialist-led Ned Clinic
Participants enrolled in specialist-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist for one year.
|
|
Experimental: Nurse-led Ned Clinic
Participants enrolled in the nurse-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist.
In addition, men will be asked to complete another set of PROs that will be monitored by a trained oncology nurse, in between their specialist visits.
|
Participants enrolled in the Nurse-led Ned Clinic will receive virtual PCa survivorship follow-up care from both their specialist and an oncology nurse for one year.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in unmet needs
Time Frame: Measured at Baseline, 6 months, 1 year
|
Assessed by Cancer Survivors' Unmet Needs (CaSUN) questionnaire.
The questionnaire is a 42-item instrument that captures the current needs of a cancer survivor, such as medical care, quality of life, emotional and relationship needs and their current view of life.
|
Measured at Baseline, 6 months, 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes to Participant's Health Status
Time Frame: Measured at Baseline, 6 months, 1 year
|
Assessed by the EQ5D-5L questionnaire.
This questionnaire contains 6 questions which assess the patient's health status by understanding how they feel about their mobility, self-care, usual activities, pain/discomfort and levels of anxiety or depression.
|
Measured at Baseline, 6 months, 1 year
|
Changes in Prostate Cancer health related quality of life
Time Frame: Measured at Baseline, 6 months, 1 year
|
Assessed by the Expanded Prostate Cancer Index Composite Short Form (EPIC-26).
The questionnaire is a 13-item instrument that captures the side effects and symptoms that might affect the quality of life in patients with prostate cancer patients.
|
Measured at Baseline, 6 months, 1 year
|
Changes in overall health related quality of life
Time Frame: Measured at Baseline, 6 months, 1 year
|
Assessed by the Functional Assessment of Cancer Therapy for Prostate Cancer patients (FACT-P).
This questionnaire is a 39-item instrument that assesses the quality of health-related well-being for patients with prostate cancer.
|
Measured at Baseline, 6 months, 1 year
|
Changes in Psychological Wellbeing
Time Frame: Measured at Baseline, 6 months, 1 year
|
Assessed by the General Health Questionnaire (GHQ-12).
This questionnaire contains 12-questions that ask prostate cancer patients how they have been feeling in the past weeks.
|
Measured at Baseline, 6 months, 1 year
|
Changes in willingness to self-manage
Time Frame: Measured at Baseline and 1 year
|
Assessed by the Patient Activation Measure Questionnaire (PAM-13).
This questionnaire is a 13-item instrument that quantifies a patient's readiness to engage in their own self-management.
|
Measured at Baseline and 1 year
|
Changes to satisfaction with care
Time Frame: Measured at Baseline and 1 year
|
Assessed by the Care Satisfaction Questionnaire.
This questionnaire is an 11-item instrument used to quantify experience and acceptability of follow-up care.
|
Measured at Baseline and 1 year
|
Changes in health behaviours
Time Frame: Measured at Baseline and 1 year
|
Assessed by the Health Behaviour Questionnaire.
This questionnaire is used to determine participant health practices (e.g.
smoking, fitness, alcohol consumption).
|
Measured at Baseline and 1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-5188
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
Clinical Trials on Nurse Ned Clinic
-
Spenshult HospitalThe Swedish Rheumatism Ass; County Council of Halland, SwedenUnknownRheumatic DiseasesSweden
-
University of Michigan Rogel Cancer CenterWithdrawn
-
Vastra Gotaland RegionGöteborg UniversityCompleted
-
University of EdinburghAllergy UKUnknown
-
University College CorkSidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Cork University... and other collaboratorsActive, not recruitingCervical Cancer | Breast Cancer | Endometrial Cancer | SurvivorshipIreland
-
Centre for Global eHealth InnovationUniversity Health Network, Toronto; Trillium Health PartnersUnknown
-
University of BristolCompleted
-
Manchester University NHS Foundation TrustCompletedGrowth Hormone Treatment | Short StatureUnited Kingdom
-
St George's, University of LondonCompletedHypertensionUnited Kingdom
-
Macfarlane Burnet Institute for Medical Research...National Health and Medical Research Council, Australia; Gilead Sciences; The... and other collaboratorsRecruitingHepatitis C | Hepatitis C, Chronic | Chronic Hepatitis cAustralia